Aktuella utlysningar, vecka 4, 2023
Grants Office tipsar om aktuella anlag
Svenska och nordiska anslag
Erik and Edith Fernström Foundation for Medical Research - extended application period until February 7.
The scholarships will be awarded for research at top foreign research institutions. The primary purpose is to support researchers whose research objectives cannot be achieved at corresponding Swedish institutions, but that can be expected to generate results of value for ongoing medical research in Sweden.
Researchers and registered doctoral students at Karolinska Institutet are eligible to apply for a scholarship. Exchanges with Karolinska Institutet’s partner universities and institutions are given a certain degree of priority.
The application must be submitted digitally. The online form will be available through KI Prisma
Extended application period until 2 pm on February 7.
Ming Wai Lau Centre for Reparative Medicine Seed Grant Programme
This funding mechanism is intended to promote new research activities in stem cell differentiation, reprogramming and biomanufacturing toward translational application among researchers employed by Karolinska Institutet (KI). Five proposals will be funded with a budget of 1 000 000 Swedish kronor per year for a maximum period of three years. The funding is meant to support new collaborative projects, not continuation of ongoing collaborations. The Seed Grant team must have a minimum of two group leaders from different KI departments with an equal partnership and budget splits.
Submission deadline: 21 April 2023
Support scientific eye and vision research in order to prevent and treat eye diseases and to effectively utilise residual vision. Research scholarships worth SEK 20,000 each are available, as well as project grants worth between SEK 40,000 and SEK 250,000 each.
Closing date: February 28, 2023
Forskningsanslag - Hjärnfonden
Stödjer kvalificerad forskning om hjärnan och övriga nervsystemet samt sjukdomar, skador och funktionsnedsättningar i hela nervsystemet. Det går även att erhålla forskningsbidrag med särskilt stöd från Team Rynkeby-God Morgon Skolloppet. Forskningen ska i det fallet vara inriktad mot psykisk ohälsa hos barn och unga. Behöriga att söka är forskare med flera års erfarenhet av forskning efter disputationen och med anställning eller tydlig anknytning till svenskt lärosäte t. ex. verksamhet vid universitetsklinik. Minst hälften av arbetstiden under anslagstiden måste vara förlagd till Sverige. Anslag uppgår till SEK 600,000 under ett, två, eller tre år.
Closing date: March 1, 2023
SSF 2023 Call for EU Horizon Europe application support - The Swedish Foundation for Strategic Research
The call aims to promote internationalization of Swedish research by stimulating increased Swedish participation in HEU Pillar 2 Global Challenges & European Industrial Competitiveness. The HEU-projects must be of strategic relevance for Sweden, i.e., benefit the future competitiveness of Sweden. It is directed exclusively towards researchers in natural science, technology or medicine at Swedish universities or research institutes that apply for a HEU Pillar 2 Project Coordinator role. Grants are worth up to SEK 500,000.
Closing date: March 1, 2023
Forskningsanslag - Stiftelsen Läkare Mot AIDS Forskningsfond
Stiftelsen stöder forskning kring HIV-infektion och AIDS, särskilt aspekter avseende behandling och prevention och vaccin. Prioritet ges till projekt som har klinisk anknytning och till sökande som nyligen påbörjat sin forskning. Stöd ges normalt bara till forskning som har en tydlig anknytning till ett svenskt universitet eller sjukhus. Upp till 400 000 kr kan anslås till varje beviljat projekt.
Closing date: March 1, 2023
Travel grants for doctoral students in preclinical and clinical medical research – Swedish Society for Medical Research (SSMF)
These aim cover personal costs in connection with travel to another research institution or clinic for studies of significance to the applicant's own research project. Grants are worth up to SEK 50,000 and are granted a maximum of three times.
Closing date: 1 March 2023
CIMED projektbidrag 2024-2026
CIMED utlyser projektmedel för kliniska forskningsprojekt för perioden 2024-2026.
Bidragsbelopp är 300 000 kr till 1 000 000 kr/år för 1 upp till 3 år.
CIMED projektmedel kan sökas av forskare med sin verksamhet knuten till en av institutionerna på Campus Flemingsberg, KI.
Utlysningsperiod: 9 januari 2023 - 5 mars 2023, kl.24.00. Support ges fram till fredag 3 mars kl.15:00.
Ansökan sker genom Region Stockholms researchweb
Stipendier - American Dental Society of Sweden (ADSS)
- ADSS forskningsstipendium: kan sökas av personer som forskar eller undervisar inom odontologi i Sverige för deltagande i vetenskapliga kongresser under det kalenderår som ansökan avser.
Closing date: February 28, 2023
- Sandbloms stipendium: kan sökas av tandläkare med svensk legitimation som bör vara medlem av Svenska Tandläkare-Sällskapet. Stipendiet kan användas för att finansiera studieresa (t ex postdoc) under minst 6 månader till officiellt erkänt universitet i USA.
Closing date: March 31, 2023
Projektanslag för cancerforskning – Sjöbergstiftelsen
Sjöbergstiftelsen stödjer cancerforskning genom att finansiera forskningsprojekt inom området samt genom att dela ut ett internationellt stipendium, Sjöberpriset, på en miljon USD till cancerforskare.
2023 kommer Sjöbergstiftelsen att ge bidrag till cancerforskning inom områdena:
- Förebyggande åtgärder och omvårdnad inklusive komplementär och integrativ medicin och åtgärder mot långsiktiga komplikationer
- Tidig diagnostik samt svårbehandlad cancer med dålig prognos och även "drug repurposing".
Inom ovanstående forskningsområden kan olika forskargrupper inom landets universitetssjukhus lämna in en gemensam större ansökan avseende bidrag till uppbyggnad och konsolidering av nationellt nätverk för forskningen. Ansökan ska ha en stark koppling mellan translationell och klinisk forskning med involvering av väl fungerande kvalitetsregister och biobanker kopplade till konkreta kliniska frågeställningar, företrädesvis inom ramen för nationella kliniska studier. Även andra typer av multiprofessionell klinisk samverkan kan vara aktuellt, såsom studier avseende vård- och terapiinriktade studier.
I enlighet med donatorns önskemål välkomnas ansökningar som avser okonventionella mediciner/behandlingsmetoder.
Closing dates: Pre-proposal March 31, 2023; Full grant application September 10, 2023.
Anslag för forsknings- eller utbildningsprojekt
Erling-Perssons Stiftelse ger anslag till forsknings- eller utbildningsprojekt inom medicin samt inom intresseområden som ligger nära så som entreprenörskap ämnet. Stiftelsen ser helst att projekten har en tvärvetenskaplig karaktär. Tillämpningsinriktad forskning prioriteras. Stiftelsen stödjer inte ren grundforskning. Anslag kan utgå till klart identifierbara ändamål med inriktning på utsatta barns situation. Sökta projekt kan normalt vara 2-5 år långa och ska vara tydligt avgränsade (ej del av löpande verksamhet, ej forskningsprogram). Huvudsökande bör ha en senior position inom sin organisation.
Det finns inga bestämda gränser för sökbart belopp. Stiftelsen ger ej medel till centrum- eller nätverkssatsningar, mötes- eller konferensverksamhet, individuella postdoktors- eller doktorandstudier och verksamhet som ska bekostas av kommuner, landsting eller staten.
Sista ansökningsdag på områdena Undervisning & utbildning samt Barns och ungas utveckling ska för kommande ansökningsomgång vara stiftelsen tillhanda 10 mars 2023.
Stiftelsen sammanträder för beslut om anslag i september/oktober och februari/mars. Ansökningar på område Vetenskap & Forskning ska för kommande ansökningsomgång vara stiftelsen tillhanda 17 april 2023.
ERC Advanced Grants 2023 call
On December 8th, 2022, the European Research Council (ERC) opened its call for applications for ERC Advanced Grants 2023. These support ground-breaking, high-risk high-gain projects carried out by an established, leading principal investigator in any field of research. Applicants are expected to be active researchers who have a track record of significant research achievements in the last 10 years and should be exceptional leaders in terms of originality and significance of their research contributions.
Each grant is worth up to €2.5m over five years. An additional €1m may be requested.
Submission deadline: 23/05/2023
Please contact Grants Office if you are interested in applying with KI as host institution (firstname.lastname@example.org)
• ERC Advanced Grants official web page -- Who can apply and with what type of project?
• KI ERC web pages -- Applying for an ERC grant with KI as Host Institution
Research grants on Down's syndrome and other intellectual disabilities from genetic origin -- Fondation Jérôme Lejeune, FR
This supports fundamental, translational and clinical research projects that will strengthen the understanding, deepen the knowledge and/or will explore new therapeutic approaches for Down syndrome and other genetic diseases with intellectual disability. There are two types of funding schemes:
- Pilot or exploratory grants - For early-stage research projects built on preliminary data or small projects that complement larger primary projects. 50.000 €
- Advanced grants - For larger breakthrough projects with substantial preliminary data. 80.000 €
Closing date 24 February 2023
This supports the development of tools, technologies and approaches that benefit the replacement, refinement, and reduction of animals in research, with a focus on animal use in the key areas of endocrine disruption and CAR-T cell therapy. The 2022 challenges are:
• Challenge 42 - T-ALERT: Animal-free tumourigenicity assessment of CAR-T and other genetically modified T cells;
• Challenge 43 - Thyroid Tox: Development of an in silico model to predict thyroid receptor mediated human endocrine disruption.
Any public or private UK or EU body may apply. Applications can be from single organisations, investigators or from consortia. The lead applicant must be UK or EU based.
The total budget is £1.2M. Challenge 42 T-ALERT is a two-phase challenge with funding up to £1M for up to three years' contract. Challenge 43 Thyroid Tox is a single-phase challenge with funding up to £100,000 for up to 18 months' contract.
Closing date 27 February 2023 (Forecast)
Meyer award -- ResOrtho Foundation, CH
This recognises transformatory discoveries, innovations or disruptions in the diagnosis prevention or treatment of pathologies of the musculoskeletal system. The prize is given for singular discoveries, patient relevant innovations, or paradigm shifting, disruptive new and proven concepts or methods.
The award is worth CHF 30,000.
Closing date 28 February 2023 (Forecast)
Young investigator grant -- International Association for the Study of Lung Cancer (IASLC), FR
This supports the training of early-career researchers who wish to pursue career in lung cancer diagnosis, treatment or laboratory research, as well as other aspects of the study of lung tumours.
Applicants must be within five years of initial faculty appointment. They also must be members of the association. Researchers from commercial organisations may not apply.
The grant is worth USD 50,000.
Closing date 03 March 2023 (Forecast)
Federal Funding agencies
Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed): NIH
Scientific discovery is often catalyzed by technological innovations. The kidney, urinary tract, blood, and blood-forming organs present unique technological challenges. To address these challenges, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to develop novel tools and technologies that enable new lines of scientific inquiry and/or treatment, prevention, or diagnosis of kidney, urologic, or hematologic diseases.
This Funding Opportunity Announcement (FOA) is intended to support tool or technology development projects, opening new areas of science or translational research. The projects supported by this FOA could involve proof-of-concept studies, prototyping, optimization of a technology for the unique anatomy or physiology of these organ systems, and refinement of technical specifications for subsequent deployment of the technology in laboratory or clinical settings.
Deadline: May 8, 2023. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-20-140
Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed): NIH
This Funding Opportunity Announcement (FOA) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding, scientific priorities. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the NIDDK. Likewise, interrogations into biological mechanisms underlying HIV reservoirs in NIDDK-relevant tissues are important for developing strategies for long-term viral suppression or eradication. Finally, health-impeding social determinants of health may affect CCCs or viral reservoirs within NIDDK's mission through multiple pathways.
Deadline: Standard AIDS dates apply. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-21-062
In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed): NIH
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes phenotypic data for 8260 knockout genes. Overall, the IMPC hopes to generate a null mutant and undertake broad-based phenotyping for every gene in the mouse genome. About 30% of these strains are expected to be either embryonic or perinatal lethal, or subviable. However, a large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.
Deadline: June 5, 2023. Applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-23-074
Postdoctoral Fellowships, Cancer Research Institute, US
The CRI Postdoctoral Fellowship Program provides three years of critical financial support and continued career training to the most promising young scientists in basic and tumor immunology as part of our lifesaving work in cancer immunotherapy research. There are three tracks within the CRI Postdoctoral Fellowship Program:
- CRI Irvington Postdoctoral Fellowship: Furthers career development and supports laboratory research for promising young scientists working under the mentorship of leading immunologists.
- CRI Irvington Postdoctoral Fellowship to Promote Racial Diversity: Furthers career development and supports laboratory research for promising young scientists who identify as Black or African American, Hispanic or Latino/a American, or American Indian or Alaska Native, working under the mentorship of leading immunologists.
- NEW: CRI Immuno-Informatics Postdoctoral Fellowship: Supports qualified young scientists at academic research institutions around the world who wish to receive dual training in immunology and data science.
Eligibility: Applicants with 5 or more years of relevant postdoctoral experience at the time of award activation are not eligible, with the exception of MD applicants, who should not include years of residency in this calculation. Only in exceptional circumstances will applicants who have already spent 3 or more years in a sponsor’s laboratory by the start date of fellowship be considered for a fellowship award.
Budget: Fellowships are for three years. Newly awarded fellowships provide a stipend of $55,000 for the first year, $57,000 for the second year, and $59,000 for the third year. An allowance of $5,000 per year is allotted to the host institution for use at the sponsor’s discretion to help pay for the fellow’s research supplies, travel to scientific meetings, health insurance, and/or childcare. Indirect costs are not covered.
Deadline: 1st March, 2023.
Translational Research Program, Jeffrey Modell Foundation, US
The purpose of this research program is: to support innovative and novel investigations in Primary Immunodeficiency focusing on translational research leading to meaningful clinical application; to advance the growing knowledge of genotype-phenotype correlations and gain a better understanding of the underlying mechanisms of immune function and dysfunction; and to support research that will lead to advancement in clinical recognition, diagnostic tools, and innovative therapies that will impact overall health outcomes and improve the quality of life of those affected by Primary Immunodeficiency.
Grants with the following focus will be strongly considered for awards: Novel Primary Immunodeficiency defects; Innovative approaches to early diagnosis - Novel therapeutic strategies; Translational impact on patient health (i.e., how a patient will benefit); Reach of the proposed project (i.e., how many patients might benefit); Projects that currently do not have funding and would be otherwise difficult to advance without this award.
Eligibility: The Jeffrey Modell Foundation encourages all international and U.S. investigators with the appropriate knowledge and research skill level to apply for this grant. Applications submitted by investigators with vast expertise in Primary Immunodeficiency, as well as young investigators with robust scientific merit will be considered. JMF encourages investigators who are not currently receiving funding from the National Institutes of Health to apply.
Budget: The number of awards per cycle will be dependent on the strength and merit of applications received and the availability of funds. Individual awards may total up to $250,000 over a two-year period. Funds are not to exceed $125,000 per year per project. Indirect costs are not covered.
Deadline: LOI - 15th March, 2023; full application (by invitation) - 6th July, 2023.
Clinical Science Research Grant, International Society for the Study of the Lumbar Spine, Int
The research proposal should be in the field of clinical science. At least one investigator must be a current ISSLS member. The research proposal will be judged on significance, quality of the hypothesis, experimental protocol and feasibility. Projects that intend to use the ISSLS funding to lead to other larger funding sources are encouraged but must have a strong plan for further funding.
Eligibility: The principal investigator must be 45 years of age or younger. The recipient will provide a written progress report to the Research Grant Committee, four weeks prior to the following year’s Annual Meeting and make a presentation during the Fellowship Ceremony of that Annual Meeting.
Budget: The winning proposal will receive a US $20,000 award. The research funds cannot be used as a salary for any of the investigators.
Deadline: 28th February, 2023.
Junior Investigator Global ATTR Amyloidosis Research ASPIRE, Pfizer, US
Pfizer is interested in supporting research proposals that advance our understanding of the epidemiology, basic science and early diagnosis and treatment of ATTR amyloidosis through research focused in the following areas: Epidemiologic evaluations for ATTR amyloidosis; Approaches for the early identification and follow up of ATTR amyloidosis patients; RW efficacy and safety of tafamidis in the clinical setting for the management of ATTR amyloidosis; Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy and polyneuropathy); Pathophysiology.
Eligibility: The applicant (PI) must be a junior investigator with a professional terminal degree (MD and/or PharmD or equivalent). Applicants must have obtained their terminal degree*less than 10 years ago. *Terminal degree: end of training (i.e. residency/fellowship). The 10 years will begin after
someone completes their training and begin a real teaching or patient care-focused job. Applicant must be developing their research careers in ATTR Amyloidosis. Applicant must have a mentor or senior investigator participate as a co-investigator.
Budget: Individual projects requesting up to $75,000 USD/year for 1 to 2 years will be considered. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
Deadline: 21st March, 2023.